New York · 82103

Alpha-1-Antitrypsin (protein) Blood Test, Total in New York

New York Medicare Avg
$13.16
0% above national avg
National Medicare Avg
$13.13
All states combined
Billed Charge (NY)
$107.70
What providers submit
Est. Commercial (NY)
$32.91
National avg: $29.40
Est. Cash / Self-Pay (NY)
$39.49
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

1.5K
Services in NY
28
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in New York

Provider Medicare Services
Northwell Health Laboratories $13.17 808
Sunrise Medical Laboratories, Inc. $13.17 377
Laboratory Alliance Of Central New... $13.09 144
Empire City Laboratories, Inc $13.17 37
Enzo Clinical Labs, Inc. $13.17 25
Lenco Diagnostic Laboratories,inc. $13.17 18
Sherman Abrams Laboratory Inc $13.17 14

New York Pricing in Context

In New York, CPT code 82103 (Alpha-1-Antitrypsin (protein) Blood Test, Total) carries an average Medicare payment of $13.16 — 0% above the national benchmark of $13.13. 28 providers across the state submitted claims for this procedure in 2023, performing 1.5K total services. Individual payments in NY ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in New York is $107.70, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New York sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Blood Test procedures, the estimated commercial insurance price in New York lands near $32.91, with self-pay cash prices typically around $39.49. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Alpha-1-Antitrypsin (protein) Blood Test, Total cost in New York?

The average Medicare payment for Alpha-1-Antitrypsin (protein) Blood Test, Total in New York is $13.16, which is 0% above the national average of $13.13. Providers in NY typically bill $107.70 for this procedure.

What does Alpha-1-Antitrypsin (protein) Blood Test, Total cost with insurance in New York?

With commercial insurance in New York, Alpha-1-Antitrypsin (protein) Blood Test, Total costs an estimated $32.91. Without insurance, the estimated cash price is $39.49. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Alpha-1-Antitrypsin (protein) Blood Test, Total in New York?

28 providers in New York billed Medicare for Alpha-1-Antitrypsin (protein) Blood Test, Total in 2023, performing 1.5K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Alpha-1-Antitrypsin (protein) Blood Test, Total cheaper in New York than the national average?

No — Alpha-1-Antitrypsin (protein) Blood Test, Total costs 0% above the national average in New York. The state average Medicare payment is $13.16 compared to $13.13 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial